If you believe in the transformative actions of AI in healthcare, this trio will reset your horizon trajectory

Artificial intelligence in healthcare is one of the most obvious ways that technology is meeting real needs, especially as rising energy prices, geopolitical tensions and persistent inflation keep pressure on costs and productivity. As many industries face slowing business and rising input prices, AI tools that enable better diagnostics, smoother hospital operations, and faster drug discovery are having a direct impact on efficiency and outcomes. This screening tool focuses on companies that are applying AI to these problems, helping you focus on companies related to long-term changes in the way care is delivered. Below you will see 3 stocks from the Transformative AI Healthcare stock list.

Preview: Medtronic is a leading medical device company that provides surgeons and clinicians with products such as pacemakers and defibrillators, spinal and brain implants, surgical tools and robots, and insulin pumps and glucose monitors for the treatment of diabetes in the United States and international markets.

Operations: Medtronic generates most of its revenue in the areas of cardiovascular disease ($13.5 billion), neuroscience ($10.2 billion), medical-surgical ($8.6 billion), and diabetes ($3.0 billion), with the United States contributing $17.8 billion and the rest of the world contributing $17.6 billion.

Market capitalization: 110.8 billion US dollars

Investors interested in AI in healthcare may find Medtronic interesting as its core cardiac, neurosurgical and surgical device franchises are increasingly tied to software, data and robotics, from AI-powered surgical video platforms to the Stealth AXiS navigation system and ALERT trials in heart valve care. The company backs this up with significant R&D, a record long dividend yielding 3.29%, and earnings that analysts expect to grow faster than its recent 5-year trend. At the same time, competition in diabetes technology, a history of product recalls and reliance on external borrowing keep risk on the table. The real opportunity for you lies in how these forces and pressures work together.

Medtronic’s AI-related devices, robotics and software could tell a different story than that suggested by its overall dividend yield. Find out how analyst expectations align in the analyst forecasts for Medtronic and what could be hiding underneath.

Preview: Insmed focuses on therapies for serious and rare diseases, with an approved treatment for lung infections, ARIKAYCE, and a deep pipeline targeting bronchiectasis, pulmonary hypertension, Duchenne muscular dystrophy, amyotrophic lateral sclerosis and other difficult-to-treat conditions.

Operations: Insmed generates approximately $606.4 million in revenue from therapies for rare disease patients, including approximately $453.0 million from the United States and $153.5 million from international markets.

Market capitalization: 35.2 billion US dollars

Insmed stands out in AI-driven healthcare because its core respiratory and rare disease portfolio is already commercial, but remains closely tied to upcoming data and approvals that could reshape the business, from brensocatib in bronchiectasis to TPIP in pulmonary hypertension and potential expansion of the ARIKAYCE label. Analysts highlight the potential for revenue and profit growth, but this depends on approvals, payer support and successful market access, while the company remains loss-making and dependent on external financing and new equity capital. For investors willing to take that risk, the combination of multiple late-stage programs, growing international reach and analyst targets presents a story that is more complex than a simple high-growth biotech label would suggest.

Insmed’s late-stage pipeline and focus on rare diseases may obscure a broader story about how all these moving parts fit together. See how the analysis report for Insmed explains the upside potential as well as the risks that could change the outlook.

Preview: Stryker is a global medical technology company that provides hospitals and clinicians with surgical equipment, neurotechnology devices, AI-assisted virtual care and communication platforms, and orthopedic implants for joint replacements and trauma care.

Operations: Stryker generates approximately $9.5 billion in orthopedics and $15.6 billion in MedSurg and neurotechnology, with most revenue coming from the United States and additional contributions from Europe, the Middle East, Africa, Asia Pacific and other international markets.

Market capitalization: 127.2 billion US dollars

Stryker sits at the intersection of hardware and software in healthcare, combining orthopedic implants and intelligent robots like Mako with AI-assisted hospital and virtual care platforms. Its balance sheet carries debt and recent cyberattacks highlight how exposed connected hospital providers can be. Earnings, return on equity forecasts and continued investments in connected operating rooms, stroke care and SmartHospital digital services indicate an evolving business. For investors interested in AI health tools backed by an established and profitable medical device franchise, the key consideration is how this mix of growth, risk and valuation plays out beyond the headlines.

Mako robotics and SmartHospital services hint at an AI engine that could mask where the real value lies. See how the analyst forecasts for Stryker reframes Stryker’s future or exposes the pressure point that investors rarely discuss.

The three stocks covered here are just a starting sample, with full Healthcare Stock Analyzer Transformative Artificial Intelligence (AI) surfacing 34 other companies where AI is reshaping diagnostics, care delivery and profitability with equally compelling stories. Use Simply Wall St to identify, filter and analyze the specific enablers and stories that matter to you so you can focus on your most compelling AI healthcare ideas.

Take control of your investment journey

If Stryker or any of these companies sounds like a great opportunity for you, sign up for FREE on Simply Wall St and add your top picks to a Watchlist to monitor the stock price relative to fair value to determine the ideal entry point. Once your move is complete, manage your assets with our Wallet Command Center which filters out the noise to provide only the most critical and actionable updates. Throughout your journey, our Community lets you filter the best ideas from thousands of investor perspectives. By uncovering catalysts and hidden risks early, you will accelerate your decision-making and stay ahead of the market.

Curious about alternative courses of action?

New ideas can quickly move from calm to emergence, and once momentum is clear, the best entry points may disappear. Review them under the radar and determine if any fit your approach.

This Simply Wall St article is general in nature. We provide commentary based on historical data and analyst forecasts only using unbiased methodology and our articles are not intended to constitute financial advice. It does not constitute a recommendation to buy or sell shares and does not take into account your objectives or your financial situation. Our goal is to provide you with targeted, long-term analysis based on fundamental data. Note that our analysis may not take into account the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Any feedback on this article? Worried about the content? Get in touch with us directly. You can also send an email editorial-team@simplywallst.com